A Multi-Centre RCT of the Axium® Neurostimulator for the Treatment of Chronic Inguinal Pain Following Surgery (SMASHING)

January 30, 2017 updated by: Frederique Mol, Maxima Medical Center

A Randomised Controlled Trial to Evaluate the Efficacy of the Spinal Modulation Axium® NeuroStimulator THerapy as a Treatment for Persistent INGuinal Pain Following Surgical Intervention: SMASHING

24-SMI-2014 is a Randomised Controlled Trial with an optional one way cross-over comparing Conservative Medical Management (CMM) to treatment with the Axium neurostimulator + CMM. Subject population is chronic inguinal pain refractory to previous surgical intervention (neurectomy).

Study Overview

Study Type

Interventional

Enrollment (Actual)

18

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Eindhoven, Netherlands
        • Maxima Medisch Centrum

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subject is at least 18 years old
  2. Subject is able and willing to comply with the follow-up schedule and protocol
  3. Chronic inguinal pain following Pfannenstiel Incision or Open Inguinal Hernia Repair for at least 6 months
  4. Previously undergone neurectomy procedure as a treatment for chronic inguinal pain
  5. Minimum daily average baseline pain rating of 5 out of 10 in the inguinal area on an 11-point NPRS
  6. Subject is able to provide written informed consent
  7. Meets of the inclusion criteria for the implantation of a neurostimulation system as set out by the Dutch Neuromodulation Society
  8. Subject has been screened by a multi-disciplinary panel including the designated psychologist of the Máxima Medical Center and deemed suitable for implantation

Exclusion Criteria:

  1. Female subject of childbearing potential is pregnant/nursing or plans to become pregnant during the course of the Trial
  2. Escalating or changing pain condition within the past month as evidenced by investigator examination
  3. Subject has had injection therapy or radiofrequency treatment of a target neural structure within the past 3 months
  4. Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump
  5. Subject is unable to operate the device
  6. Subjects currently has an active infection
  7. Subject has participated in another clinical investigation within 30 days
  8. Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation
  9. Subject has a current or on going condition, which will probably require MRI investigation sometime in the following 2 years
  10. Subject has had a spinal surgical procedure at or between vertebral levels T10-L2
  11. Subject has been diagnosed with cancer in the past 2 years, except for skin malignancies.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Conservative Medical Management
Continued medical management restricted to exclude interventional pain treatments
ACTIVE_COMPARATOR: Axium Group
As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of subjects experiencing ≥50% reduction in average daily pain intensity in the Axium Group as compared to the CMM only group using an eleven point (0-10) numerical pain rating scale (NPRS)
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2014

Primary Completion (ANTICIPATED)

July 1, 2017

Study Completion (ANTICIPATED)

October 1, 2017

Study Registration Dates

First Submitted

January 9, 2015

First Submitted That Met QC Criteria

January 23, 2015

First Posted (ESTIMATE)

January 29, 2015

Study Record Updates

Last Update Posted (ESTIMATE)

February 1, 2017

Last Update Submitted That Met QC Criteria

January 30, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 24-SMI-2014

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Inguinal Pain Refractory to Previous Surgical Intervention (Neurectomy)

Clinical Trials on Implantation with the commercially available Axium neurostimulator

Subscribe